

Basic information	
2018/0118(NLE) NLE - Non-legislative enactments Decision	Awaiting final decision
Subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures Subject 7.30.30.04 Action to combat drugs and drug-trafficking	

Key players				
European Parliament	Committee responsible		Rapporteur	Appointed
	LIBE	Civil Liberties, Justice and Home Affairs	ŠKRIPEK Branislav (ECR)	20/06/2018
			Shadow rapporteur HORTEFEUX Brice (PPE) HEDH Anna (S&D) PAGAZAURTUNDÚA Maite (ALDE) ANDERSON Martina (GUE /NGL)	
Council of the European Union				
European Commission	Commission DG		Commissioner	
	Migration and Home Affairs		AVRAMOPOULOS Dimitris	

Key events			
Date	Event	Reference	Summary
30/04/2018	Initial legislative proposal published	COM(2018)0253 	Summary
11/06/2018	Legislative proposal published	09420/2018	Summary
02/07/2018	Committee referral announced in Parliament		
30/08/2018	Vote in committee		
03/09/2018	Committee report tabled for plenary, 1st reading/single reading	A8-0271/2018	Summary
11/09/2018	Decision by Parliament	T8-0320/2018	Summary

11/09/2018	Results of vote in Parliament		
------------	-------------------------------	---	--

Technical information	
Procedure reference	2018/0118(NLE)
Procedure type	NLE - Non-legislative enactments
Procedure subtype	Consultation of Parliament
Legislative instrument	Decision
Other legal basis	Rules of Procedure EP 165
Stage reached in procedure	Awaiting final decision
Committee dossier	LIBE/8/13013

Documentation gateway				
European Parliament				
Document type	Committee	Reference	Date	Summary
Committee draft report		PE623.813	21/06/2018	
Committee report tabled for plenary, 1st reading/single reading		A8-0271/2018	03/09/2018	Summary
Text adopted by Parliament, 1st reading/single reading		T8-0320/2018	11/09/2018	Summary
Council of the EU				
Document type	Reference	Date	Summary	
Legislative proposal	09420/2018	11/06/2018	Summary	
European Commission				
Document type	Reference	Date	Summary	
Initial legislative proposal	COM(2018)0253 	30/04/2018	Summary	

Additional information			
Source	Document	Date	
European Commission	EUR-Lex		

Subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-

methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures

2018/0118(NLE) - 03/09/2018 - Committee report tabled for plenary, 1st reading/single reading

The Committee on Civil Liberties, Justice and Home Affairs adopted the report by Branislav ŠKRIPEK (ECR, SK) on the draft Council implementing decision on subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

The committee recommended that Parliament **approve the Council draft**.

The risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

Subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures

2018/0118(NLE) - 30/04/2018

PURPOSE: to subject the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

PROPOSED ACT: Council Implementing Decision.

ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

BACKGROUND: the risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

They are both **synthetic opioids** and are structurally related to fentanyl, a controlled substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain management. The acute toxicity of cyclopropylfentanyl and methoxyacetylfentanyl are such that it can cause severe harms to the health of individuals.

Cyclopropylfentanyl has been available in the Union since at least June 2017 and has been detected in six Member States who reported 140 seizures in total between June 2017 and January 2018. 77 deaths have been reported by two Member States where exposure to cyclopropylfentanyl was confirmed.

Methoxyacetylfentanyl has been available in the Union since at least November 2016 and has been detected in eleven Member States who reported 44 seizures in total between June and December 2017. 13 deaths have been reported by four Member States where exposure to methoxyacetylfentanyl was confirmed.

Both cyclopropylfentanyl and methoxyacetylfentanyl appear to be sold online in small and wholesale amounts, under the guise of a "research chemical" or as "legal" replacement to illicit opioids, mainly as a powder or as a solution in ready-to-use nasal sprays.

The available evidence and information on the **health and social risks** that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

CONTENT: the draft Council decision aims to subject the new psychoactive substances cyclopropylfentanyl and methoxyacetylfentanyl to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

Subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures

2018/0118(NLE) - 11/09/2018 - Text adopted by Parliament, 1st reading/single reading

The European Parliament adopted by 635 votes to 11, with 37 abstentions, following the consultation procedure, a legislative resolution on the draft Council implementing decision on subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetyl fentanyl) to control measures.

Parliament approved the Council draft which aims to subject the new psychoactive substances **cyclopropylfentanyl** and **methoxyacetyl fentanyl** to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

Subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetyl fentanyl) to control measures

2018/0118(NLE) - 11/06/2018 - Legislative proposal

PURPOSE: to subject the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetyl fentanyl) to control measures.

PROPOSED ACT: Council Implementing Decision.

ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

BACKGROUND: the risks of cyclopropylfentanyl and methoxyacetyl fentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

They are both **synthetic opioids** and are structurally related to fentanyl, a controlled substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain management. The acute toxicity of cyclopropylfentanyl and methoxyacetyl fentanyl are such that it can cause severe harms to the health of individuals.

Cyclopropylfentanyl has been available in the Union since at least June 2017 and has been detected in six Member States who reported 140 seizures in total between June 2017 and January 2018. 77 deaths have been reported by two Member States where exposure to cyclopropylfentanyl was confirmed.

Methoxyacetyl fentanyl has been available in the Union since at least November 2016 and has been detected in eleven Member States who reported 44 seizures in total between June and December 2017. 13 deaths have been reported by four Member States where exposure to methoxyacetyl fentanyl was confirmed.

Both cyclopropylfentanyl and methoxyacetyl fentanyl appear to be sold online in small and wholesale amounts, under the guise of a "research chemical" or as "legal" replacement to illicit opioids, mainly as a powder or as a solution in ready-to-use nasal sprays.

The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetyl fentanyl to control measures across the Union.

CONTENT: the draft Council implementing decision aims to subject the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide ('cyclopropylfentanyl') and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide ('methoxyacetyl fentanyl') to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

Subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetyl fentanyl) to control measures

2018/0118(NLE) - 30/04/2018 - Initial legislative proposal

PURPOSE: to subject the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetyl fentanyl) to control measures.

PROPOSED ACT: Council Implementing Decision.

ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

BACKGROUND: the risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

They are both **synthetic opioids** and are structurally related to fentanyl, a controlled substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain management. The acute toxicity of cyclopropylfentanyl and methoxyacetylfentanyl are such that it can cause severe harms to the health of individuals.

Cyclopropylfentanyl has been available in the Union since at least June 2017 and has been detected in six Member States who reported 140 seizures in total between June 2017 and January 2018. 77 deaths have been reported by two Member States where exposure to cyclopropylfentanyl was confirmed.

Methoxyacetylfentanyl has been available in the Union since at least November 2016 and has been detected in eleven Member States who reported 44 seizures in total between June and December 2017. 13 deaths have been reported by four Member States where exposure to methoxyacetylfentanyl was confirmed.

Both cyclopropylfentanyl and methoxyacetylfentanyl appear to be sold online in small and wholesale amounts, under the guise of a "research chemical" or as "legal" replacement to illicit opioids, mainly as a powder or as a solution in ready-to-use nasal sprays.

The available evidence and information on the **health and social risks** that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

CONTENT: the draft Council decision aims to subject the new psychoactive substances (cyclopropylfentanyl and methoxyacetylfentanyl) to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.